Delving into the Latest Updates on Mimetogen Pharmaceuticals, Inc. with Synapse

Overview

Basic Info

Introduction

Mimetogen Pharmaceuticals is a company that specializes in creating small molecule drugs that mimic the effects of neurotrophin proteins. These drugs are designed to help maintain the health and growth of cells and tissues in the eye. The company offers a range of products including tyrosine kinase agonists that prevent neuronal death, small molecule tyrosine kinase receptor agonists that stimulate mucin secretion from conjuctival goblet cells, and small molecule neurotrophin mimetics that rescue retinal pigment epithelial cells from oxidative stress-induced apoptosis. Mimetogen was established in 2005 by Garth Cumberlidge and H. Uri Saragovi and is headquartered in Montreal, Canada.

Tags

Eye Diseases

Synthetic peptide

Disease domain score

A glimpse into the focused therapeutic areas

No Data

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Top 5 Drug Type	Count

Synthetic peptide	1

Top 5 Target	Count

TrkA(Nerve growth factor receptor Trk-A)	1

PURPOSETo evaluate the safety and efficacy of ophthalmic MIM-D3, a tyrosine kinase TrkA receptor agonist, in patients with dry eye.DESIGNA prospective, two-center, randomized, double-masked, placebo-controlled Phase 2 study.METHODSA total of 150 dry eye patients were randomized 1:1:1 to study medication (1% MIM-D3, 5% MIM-D3, or placebo) and dosed twice daily (BID) for 28 days. Key eligibility criteria included exacerbation in corneal staining and ocular discomfort in the Controlled Adverse Environment (CAE(SM)) on two visits, separated by 1 week of BID dosing with artificial tears. Safety and efficacy were evaluated at baseline, throughout treatment, and for 2 weeks post-treatment. The pre-specified primary outcome measures were fluorescein corneal staining post-CAE at day 28 and diary worst symptom scores over 28 days. Secondary outcomes included the pre-, post-, and the change from pre- to post-CAE fluorescein and lissamine green staining in both corneal and conjunctival regions, as well as individual diary symptoms.RESULTSThe prespecified primary endpoints were not met. Compared with placebo, fluorescein corneal staining at day 28 was significantly improved (P < 0.05) in the 1% MIM-D3 group for the assessment of change from pre-CAE to post-CAE. In addition, following CAE exposure, patients in the 1% MIM-D3 group showed significant improvements versus placebo (P < 0.05) in inferior fluorescein and lissamine green staining after 14 and 28 days. Compared with placebo, patients in the 5% MIM-D3 group reported significantly lower daily diary scores for ocular dryness (P < 0.05). In a subgroup defined by higher symptom scores during the run-in period, significant treatment effects (P < 0.05) were observed for diary symptoms for both MIM-D3 doses. Ocular adverse events were mild and not considered to be treatment-related.CONCLUSIONTreatment with topical ophthalmic MIM-D3 demonstrated protection against the effects of a CAE challenge on dry eye signs, reduced patient-reported diary symptoms, with a favorable safety profile.

100 Deals associated with Mimetogen Pharmaceuticals, Inc.

Login to view more data

100 Translational Medicine associated with Mimetogen Pharmaceuticals, Inc.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 08 Oct 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

4

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Tavilermide ( TrkA )	Keratoconjunctivitis More	Phase 3
MIM-3Aa	Eye Diseases More	Pending
Anti-MIMA2 antibody(Mimetogen Pharmaceuticals)	Glaucoma More	Pending
MIM-3Ae	Eye Diseases More	Pending
Alao (5%)	Dry Eye Syndromes More	Pending